Ahmedabad-headquartered pharma player Claris Lifesciences, which recently divested its stake in a joint venture, Otsuka Pharmaceutical India Pvt Ltd (OPIPL), might be looking at exiting the pharmaceutical business altogether.
Analysts point out that having sold its speciality injectables business to Baxter Inc last December, and now divesting its stake in the Otsuka JV, Claris would be looking at exiting the pharma business altogether.
A Mumbai-based analyst said "This is a long-term strategic decision for the company. It now has a portion of its emerging markets business, which it might look at selling as well. The company would look at exiting the pharma